A case of malignant lymphoma in a patient with high levels of CA125 and CA19-9

Pediatric Hematology and Oncology

Volumn 17, Issue 3, 2000, Pages 269-272

  Kajiume, Teruyuki ^a   Yoshimi, Shoichiro ^a   Kobayashi, Kaichiro ^a   Kataoka, Naoki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

CA125; CA19 9; Malignant lymphoma

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; CANCER GROWTH; CASE REPORT; CHILD; CLINICAL FEATURE; HUMAN; LYMPHOMA; MALE; PRESCHOOL CHILD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

EID: 0034070456     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800100276451     Document Type: Article

References (8)

1. Ohtsu T. Tumor markers in lymphoproliferative disorders. Nippon Rinsho. 1996;54:1621-1625.
2. Aulbert E, Steffens O. Serum ferritin: a tumor marker in malignant lymphomas. Onkologie. 1990;13:102-108.
3. Lazzarino M, Orlandi E, Klersy C, et al. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer. 1998;82:576-582.
4. Alagoz T, Buller RE, Berman M, et al. What is a normal CA125 level? Gynecol Oncol. 1994;53:93-97.
5. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1993;309:883-887.
6. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983;29:549-552.
7. Ritts RE Jr, Del Villano BC, Go VL, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer. 1984;33:339-345.
8. Zurawski VR Jr, Broderick SF, Pickens P, et al. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol. 1987;69:606-611.